<DOC>
	<DOCNO>NCT01640860</DOCNO>
	<brief_summary>This study design determined feasibility safety advance esophageal cancer treat docetaxel cisplatin cocurrent chemoradiotherapy . The primary end point clinical best response response rate secondary endpoint progression free survival overall survival .</brief_summary>
	<brief_title>Concurrent Chemoradiotherapy With Docetaxel Cisplatin Esophageal Cancer</brief_title>
	<detailed_description>Chemotherapy provide significant palliation symptom patient unresectable , locally advanced metastatic esophageal cancer . Cisplatin continuous infusion 5 FU , alone combine radiotherapy , frequently use regimen . The response rate report cisplatin 5 FU range 35 40 % , whereas 2-year survival rate patient locally advanced esophageal cancer range 8 55 % , mean 27 % . Therefore , need test new combination , specifically unresectable locally advanced esophageal patient , aim increase pCR rate survival . Cisplatin widely use radiosensitizer Docetaxel different cisplatin -5FU prove additive effect cisplatin supra-additive antitumor activity fluorouracil vitro murine model . To investigate feasibility combine concomitant radiation docetaxel cisplatin assess regimen 's toxicity , locoregional control rate , survival patient locally advance metastatic esophageal cancer.In study , docetaxel 25mg/m2 give 500ml normal saline , 1hr infusion , day 1,8 every 3 week . Cisplatin75mg/m2 give intravenous infusion 500 mL 5 % dextrose solution 60 minute day 1 every 3weeks.. Therapy repeat every 21 day . Radiation therapy ( 200cGy/day upto 5400 cGy ) begin first day week 1 6 week ( concomitant chemoradiation therapy ) . When investigator assume standard treatment 's response rate 50 % response experimental treatment 75 % use Simon 's two-stage optimal design significance level 5 % power 80 % , total sample size 25 least require . For total 25 subject , 11 accrue stage 1 14 stage 2 . If 6 few response observe first stage trial stop early . If 16 few response observe end trial investigation drug warrant . If investigator assume drop rate 10 % , number subject per treatment arm 28 .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . 18 &lt; age &lt; 75 year 2. histologically proven previously untreated SCC esophagus 3. WHO performance status ( PS ) ≤2 4. absolute neutrophil count≥2,000/uL , platelet count≥100,000/uL 5. adequate renal hepatic function 6 . No prior chemotherapy prior adjuvant chemotherapy finish least 6 month enrollment allow 7 . No prior radiation therapy least 4 week enrollment study 1 . Evidence distant metastases 2 . Pleural pericardial effusion 3 . Fistulisation 4 . Prior malignancy ( basal cell skin carcinoma ) 5 . Prior myocardial infarction uncontrolled infection 6 . Unstable cardiac disease despite treatment , myocardial infarction within 6 month prior study entry 7 . History significant neurologic psychiatric disorder include dementia seizures 8 . Other serious underlie medical condition could impair ability patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>combine modality therapy</keyword>
</DOC>